New safety warnings about the risk of ileus have been added to all GLP-1 receptor agonists following a TGA investigation into local reports of the gastrointestinal event.

Last week, the regulator said it had updated the product information for semaglutide (Ozempic), dulaglutide (Trulicity) and tirzepatide (Mounjaro) to include intestinal obstruction and ileus as adverse events.

The TGA has received six reports of intestinal obstruction and two each of small intestinal obstruction and ileus caused by semaglutide since 2020, according to its Database of Adverse Event Notifications.

There have also been three notifications of intestinal obstruction — including one death — for dulaglutide and one case of ileus associated with tirzepatide.